

Global Generic Drugs Market Report and Forecast 2024-2032

Market Report | 2024-07-17 | 200 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$4999.00
- Five User License \$5999.00
- Corporate License \$6999.00

Report description:

Global Generic Drugs Market Report and Forecast 2024-2032

The global generic drugs market size was valued at USD 370.3 billion in 2023. It is expected to grow at a CAGR of 6.90% during the forecast period of 2024-2032, driven by the rising incidence of chronic diseases such as diabetes and hypertension. The market is experiencing robust growth and is expected to reach USD 678.2 billion by 2032.

Global Generic Drugs Market Analysis

The global generic drugs market is a critical segment of the pharmaceutical industry, providing cost-effective alternatives to branded drugs. Generics play a vital role in healthcare by increasing accessibility to essential medicines, reducing healthcare costs, and enhancing treatment options.

Market Drivers

- ☐ Patent Expirations of Blockbuster Drugs: A significant driver of the generic drugs market is the expiration of patents on blockbuster drugs. As patents expire, generic manufacturers can produce and market cheaper versions, increasing competition and making medications more affordable for patients.
- ☐ Rising Healthcare Costs: The growing burden of healthcare costs worldwide is propelling the demand for generic drugs. Governments and healthcare providers are increasingly adopting generics to manage budgets and provide affordable treatment options to a larger population.
- ☐ Increasing Prevalence of Chronic Diseases: The rising incidence of chronic diseases such as diabetes, hypertension, and cardiovascular disorders is driving the demand for long-term medication. Generics offer a cost-effective solution for chronic disease management, contributing to market growth.
- ☐ Government Initiatives and Support: Governments across the globe are promoting the use of generic drugs through favorable policies, subsidies, and regulatory support. These initiatives aim to reduce healthcare expenditure and ensure the availability of essential drugs.
- ☐ Growing Aging Population: The global aging population is increasing the demand for various medications. Older adults often require multiple drugs for managing chronic conditions, and generics provide a more affordable option, thereby driving market growth.

Market Challenges

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- ☐Stringent Regulatory Requirements: The generic drugs market faces stringent regulatory requirements and approval processes. Manufacturers must demonstrate bioequivalence to branded drugs, which can be time-consuming and costly.
- ☐Intense Competition: The market is highly competitive, with numerous players vying for market share. This intense competition can lead to price erosion, impacting profit margins for generic drug manufacturers.
- ☐Supply Chain Disruptions: Supply chain disruptions, such as those caused by the COVID-19 pandemic, can affect the production and distribution of generic drugs. Ensuring a stable supply chain is a significant challenge for the industry.
- ☐Intellectual Property Issues: Navigating intellectual property rights and patent litigations can be challenging for generic manufacturers. Branded drug companies often employ strategies to extend their patents, delaying the entry of generics into the market.

Future Opportunities

- ☐Expansion in Emerging Markets: Emerging markets present significant growth opportunities for generic drugs due to their large populations and increasing healthcare needs. Improving healthcare infrastructure and rising awareness about generics can drive market expansion in these regions.
- ☐Biosimilars: The development and approval of biosimilars (generic versions of biologic drugs) offer a lucrative opportunity for market growth. Biosimilars can provide cost-effective treatment options for complex diseases like cancer and autoimmune disorders.
- ☐Technological Advancements: Advancements in manufacturing technologies and pharmaceutical R&D can enhance the efficiency and quality of generic drug production. Implementing innovative technologies can reduce costs and improve product offerings.
- ☐Collaborations and Strategic Alliances: Collaborations and strategic alliances between generic drug manufacturers and healthcare providers can facilitate market penetration and expand the reach of generic drugs. These partnerships can also enhance R&D capabilities and streamline the approval process.
- ☐Focus on Specialty Generics: Specialty generics, which include complex generics and injectables, represent a growing segment with high potential. Developing and marketing specialty generics can offer higher profit margins and address unmet medical needs.

Global Generic Drugs Market Trends

Here are some key trends in the global generic drugs market:

-☐Rising Adoption of Biosimilars

Biosimilars, which are generic versions of biologic drugs, are gaining traction due to their cost-effectiveness and potential to provide treatments for complex conditions such as cancer and autoimmune diseases. As patents on biologic drugs expire, the market for biosimilars is expanding rapidly.

-☐Increasing Focus on Specialty Generics

There is a growing focus on specialty generics, including complex formulations and injectables. These drugs often require advanced manufacturing processes but offer higher margins and address unmet medical needs in areas such as oncology, neurology, and cardiovascular diseases.

-☐Expansion in Emerging Markets

The generic drugs market is seeing significant growth in emerging markets such as India, China, and Brazil. These regions have large populations with increasing healthcare needs, coupled with improving healthcare infrastructure and supportive government policies promoting the use of generics.

-☐Stringent Regulatory Approvals

Regulatory bodies are implementing stricter guidelines for the approval of generic drugs to ensure their safety, efficacy, and quality. This trend is driving manufacturers to invest in high-quality manufacturing processes and robust clinical trials to meet regulatory standards.

-☐Consolidation and Mergers & Acquisitions

The market is witnessing increased consolidation, with larger pharmaceutical companies acquiring smaller generic manufacturers to expand their product portfolios and market reach. Mergers and acquisitions help companies achieve economies of scale and enhance their competitive position.

-☐Technological Advancements in Manufacturing

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Advancements in pharmaceutical manufacturing technologies, such as continuous manufacturing and 3D printing, are improving the efficiency and cost-effectiveness of generic drug production. These innovations are enabling manufacturers to scale up production and reduce costs.

- Growing Emphasis on Cost Containment

With rising healthcare costs, there is an increasing emphasis on cost containment strategies by governments and healthcare providers. Generic drugs, being more affordable than branded drugs, are becoming a preferred option to manage healthcare budgets and provide cost-effective treatment options.

Global Generic Drugs Market Segmentation

Market Breakup by Therapy Area

- Cardiovascular
- Dermatology
- Respiratory
- Oncology
- Rheumatology
- Others

The global generic drugs market by therapy area includes cardiovascular, dermatology, respiratory, oncology, rheumatology, and others. Cardiovascular generics are driven by the high prevalence of heart diseases and the need for cost-effective treatments. Dermatology benefits from rising incidences of skin conditions and increased demand for affordable topical treatments. The respiratory segment is fueled by growing cases of asthma and COPD. Oncology generics are expanding due to high cancer rates and the success of biosimilars. Rheumatology is driven by the increasing prevalence of arthritis. These segments collectively propel market growth by addressing widespread health conditions with affordable, effective therapies during the forecast period.

Market Breakup by Route of Administration

- Oral
- Injectables
- Dermal/Topical
- Inhalers
- Others

The global generic drugs market by route of administration includes oral, injectables, dermal/topical, inhalers, and others. Oral generics dominate due to ease of administration and patient compliance, driven by high demand for chronic disease management. Injectables are growing with advancements in biologics and biosimilars, offering precise and effective treatments for conditions like cancer and autoimmune diseases. Dermal/topical generics are expanding due to rising skin conditions and cosmetic treatments. Inhalers see growth from increasing respiratory diseases like asthma and COPD. These segments collectively drive market growth by providing diverse and cost-effective treatment options across various medical needs during the forecast period.

Market Breakup by Distribution Channels

- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others

The global generic drugs market by distribution channels includes hospital pharmacy, retail pharmacy, online pharmacy, and others. Hospital pharmacies dominate, driven by the high demand for generics in acute care and chronic disease management. Retail pharmacies remain crucial for widespread accessibility and patient convenience, especially in managing long-term

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

medications. Online pharmacies are rapidly growing, propelled by digital health trends, increased internet penetration, and the convenience of home delivery. Other channels, including specialty clinics and mail-order pharmacies, also contribute to the market. These distribution channels collectively enhance market growth by ensuring broad accessibility and availability of cost-effective generic drugs during the forecast period.

Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

The global generic drugs market, segmented by region, includes North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America leads due to high healthcare costs, favorable regulatory frameworks, and significant patent expirations. Europe follows, driven by government initiatives to reduce healthcare spending and promote generics. Asia Pacific experiences rapid growth from increasing healthcare access, large populations, and supportive policies. Latin America shows potential with improving healthcare systems and rising demand for affordable medications. The Middle East and Africa, emerging markets, are driven by investments in healthcare infrastructure and growing incidences of chronic diseases. These regions collectively drive market growth by enhancing the availability and affordability of generic drugs during the forecast period.

Global Generic Drugs Market Competitive Landscape

The competitive landscape of the global generic drugs market is dynamic, with key players including Teva Pharmaceutical Industries Ltd, Viatris Inc., Sun Pharmaceutical Industries Ltd, Lupin, AstraZeneca, Almirall, S.A, Takeda Pharmaceutical Company Limited, GSK plc, Bausch + Lomb, Novartis AG, Sanofi, Pfizer Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC, and Aurobindo Pharma. Common market activities include mergers and acquisitions to enhance market share and capabilities, significant research initiatives aimed at developing cost-effective generics, frequent product introductions to expand portfolios, and strategic partnerships to foster innovation and streamline manufacturing and distribution processes. These activities collectively drive competition and growth in the generic drugs market.

Key Questions Answered in the Report

- ?□What is the current and future performance of the generic drugs market?
- ?□What are the main challenges facing the generic drugs market?
- ?□What are the key drivers of the generic drugs market?
- ?□What emerging trends are shaping the future of the generic drugs market?
- ?□How does the expiration of patents on blockbuster drugs drive the generic drugs market?
- ?□How does the rising incidence of chronic diseases impact the demand for generic medications?
- ?□How are global government initiatives promoting the use of generic drugs and reducing healthcare costs?
- ?□How do biosimilars offer a lucrative opportunity for market growth in treating complex diseases?
- ?□What are the common strategies used by key players in the generic drugs market?

Key Benefits for Stakeholders

- ?□The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global generic drugs market from 2017-2032.
- ?□The research report provides the latest information on the market drivers, challenges, and opportunities in the generic drugs market.
- ?□The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- ?□Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the global generic

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

drugs industry and its attractiveness.

□□The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Generic Drugs Market Overview
 - 3.1 Global Generic Drugs Market Historical Value (2017-2023)
 - 3.2 Global Generic Drugs Market Forecast Value (2024-2032)
- 4 Global Generic Drugs Market Landscape*
 - 4.1 Global Generic Drugs: Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Global Generic Drugs: Product Landscape
 - 4.2.1 Analysis by Therapy Area
 - 4.2.2 Analysis by Route of Administration
 - 4.2.3 Analysis by Distribution Channels
- 5 Global Generic Drugs Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.2.1 Strengths
 - 5.2.2 Weaknesses
 - 5.2.3 Opportunities
 - 5.2.4 Threats
 - 5.3 Porter's Five Forces Model
 - 5.3.1 Bargaining Power of Suppliers
 - 5.3.2 Bargaining Power of Buyers
 - 5.3.3 Threat of New Entrants
 - 5.3.4 Threat of Substitutes
 - 5.3.5 Degree of Rivalry
 - 5.4 Key Demand Indicators
 - 5.5 Key Price Indicators
 - 5.6 Industry Events, Initiatives, and Trends
 - 5.7 Value Chain Analysis
- 6 Global Generic Drugs Market Segmentation (2017-2032)
 - 6.1 Global Generic Drugs Market (2017-2032) by Therapy Area
 - 6.1.1 Market Overview
 - 6.1.2 Cardiovascular
 - 6.1.3 Dermatology
 - 6.1.4 Respiratory
 - 6.1.5 Oncology

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.1.6 Rheumatology
- 6.1.7 Others
- 6.2 Global Generic Drugs Market (2017-2032) by Route of Administration
 - 6.2.1 Market Overview
 - 6.2.2 Oral
 - 6.2.3 Injectables
 - 6.2.4 Dermal/Topical
 - 6.2.5 Inhalers
 - 6.2.6 Others
- 6.3 Global Generic Drugs Market (2017-2032) by Distribution Channels
 - 6.3.1 Market Overview
 - 6.3.2 Hospital Pharmacy
 - 6.3.3 Retail Pharmacy
 - 6.3.4 Online Pharmacy
 - 6.3.5 Others
- 6.4 Global Generic Drugs Market (2017-2032) by Region
 - 6.4.1 Market Overview
 - 6.4.2 North America
 - 6.4.3 Europe
 - 6.4.4 Asia Pacific
 - 6.4.5 Latin America
 - 6.4.6 Middle East and Africa
- 7 North America Generic Drugs Market (2017-2032)
 - 7.1 North America Generic Drugs Market (2017-2032) by Therapy Area
 - 7.1.1 Market Overview
 - 7.1.2 Cardiovascular
 - 7.1.3 Dermatology
 - 7.1.4 Respiratory
 - 7.1.5 Oncology
 - 7.1.6 Rheumatology
 - 7.1.7 Others
 - 7.2 North America Generic Drugs Market (2017-2032) by Route of Administration
 - 7.2.1 Market Overview
 - 7.2.2 Oral
 - 7.2.3 Injectables
 - 7.2.4 Dermal/Topical
 - 7.2.5 Inhalers
 - 7.2.6 Others
 - 7.3 North America Generic Drugs Market (2017-2032) by Country
 - 7.3.1 United States of America
 - 7.3.2 Canada
- 8 Europe Generic Drugs Market (2017-2032)
 - 8.1 Europe Generic Drugs Market (2017-2032) by Therapy Area
 - 8.1.1 Market Overview
 - 8.1.2 Cardiovascular
 - 8.1.3 Dermatology
 - 8.1.4 Respiratory

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.1.5 Oncology
- 8.1.6 Rheumatology
- 8.1.7 Others
- 8.2 Europe Generic Drugs Market (2017-2032) by Route of Administration
 - 8.2.1 Market Overview
 - 8.2.2 Oral
 - 8.2.3 Injectables
 - 8.2.4 Dermal/Topical
 - 8.2.5 Inhalers
 - 8.2.6 Others
- 8.3 Europe Generic Drugs Market (2017-2032) by Country
 - 8.3.1 United Kingdom
 - 8.3.2 Germany
 - 8.3.3 France
 - 8.3.4 Italy
 - 8.3.5 Others
- 9 Asia Pacific Generic Drugs Market (2017-2032)
 - 9.1 Asia Pacific Generic Drugs Market (2017-2032) by Therapy Area
 - 9.1.1 Market Overview
 - 9.1.2 Cardiovascular
 - 9.1.3 Dermatology
 - 9.1.4 Respiratory
 - 9.1.5 Oncology
 - 9.1.6 Rheumatology
 - 9.1.7 Others
 - 9.2 Asia Pacific Generic Drugs Market (2017-2032) by Route of Administration
 - 9.2.1 Market Overview
 - 9.2.2 Oral
 - 9.2.3 Injectables
 - 9.2.4 Dermal/Topical
 - 9.2.5 Inhalers
 - 9.2.6 Others
 - 9.3 Asia Pacific Generic Drugs Market (2017-2032) by Country
 - 9.3.1 China
 - 9.3.2 Japan
 - 9.3.3 India
 - 9.3.4 ASEAN
 - 9.3.5 Australia
 - 9.3.6 Others
- 10 Latin America Generic Drugs Market (2017-2032)
 - 10.1 Latin America Generic Drugs Market (2017-2032) by Therapy Area
 - 10.1.1 Market Overview
 - 10.1.2 Cardiovascular
 - 10.1.3 Dermatology
 - 10.1.4 Respiratory
 - 10.1.5 Oncology
 - 10.1.6 Rheumatology

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.1.7 Others
- 10.2 Latin America Generic Drugs Market (2017-2032) by Route of Administration
 - 10.2.1 Market Overview
 - 10.2.2 Oral
 - 10.2.3 Injectables
 - 10.2.4 Dermal/Topical
 - 10.2.5 Inhalers
 - 10.2.6 Others
- 10.3 Latin America Generic Drugs Market (2017-2032) by Country
 - 10.3.1 Brazil
 - 10.3.2 Argentina
 - 10.3.3 Mexico
 - 10.3.4 Others
- 11 Middle East and Africa Generic Drugs Market (2017-2032)
 - 11.1 Middle East and Africa Generic Drugs Market (2017-2032) by Therapy Area
 - 11.1.1 Market Overview
 - 11.1.2 Cardiovascular
 - 11.1.3 Dermatology
 - 11.1.4 Respiratory
 - 11.1.5 Oncology
 - 11.1.6 Rheumatology
 - 11.1.7 Others
 - 11.2 Middle East and Africa Generic Drugs Market (2017-2032) by Route of Administration
 - 11.2.1 Market Overview
 - 11.2.2 Oral
 - 11.2.3 Injectables
 - 11.2.4 Dermal/Topical
 - 11.2.5 Inhalers
 - 11.2.6 Others
 - 11.3 Middle East and Africa Generic Drugs Market (2017-2032) by Country
 - 11.3.1 Saudi Arabia
 - 11.3.2 United Arab Emirates
 - 11.3.3 Nigeria
 - 11.3.4 South Africa
 - 11.3.5 Others
- 12 Regulatory Framework
 - 12.1 Regulatory Overview
 - 12.1.1 US FDA
 - 12.1.2 EU EMA
 - 12.1.3 INDIA CDSCO
 - 12.1.4 JAPAN PMDA
 - 12.1.5 Others
- 13 Patent Analysis
 - 13.1 Analysis by Type of Patent
 - 13.2 Analysis by Publication year
 - 13.3 Analysis by Issuing Authority
 - 13.4 Analysis by Patent Age

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 13.7 Analysis by Key Players
- 14 Grants Analysis
 - 14.1 Analysis by Year
 - 14.2 Analysis by Amount Awarded
 - 14.3 Analysis by Issuing Authority
 - 14.4 Analysis by Grant Housing Material
 - 14.5 Analysis by Funding Institute
 - 14.6 Analysis by Departments
 - 14.7 Analysis by Recipient Organization
- 15 Funding and Investment Analysis
 - 15.1 Analysis by Funding Instances
 - 15.2 Analysis by Type of Funding
 - 15.3 Analysis by Funding Amount
 - 15.4 Analysis by Leading Players
 - 15.5 Analysis by Leading Investors
 - 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
 - 16.1 Analysis by Partnership Instances
 - 16.2 Analysis by Type of Partnership
 - 16.3 Analysis by Leading Players
 - 16.4 Analysis by Geography
- 17 Supplier Landscape
 - 17.1 Market Share by Top 5 Companies
 - 17.2 Teva Pharmaceutical Industries Ltd
 - 17.2.1 Financial Analysis
 - 17.2.2 Product Portfolio
 - 17.2.3 Demographic Reach and Achievements
 - 17.2.4 Mergers and Acquisitions
 - 17.2.5 Certifications
 - 17.3 Viatris Inc.
 - 17.3.1 Financial Analysis
 - 17.3.2 Product Portfolio
 - 17.3.3 Demographic Reach and Achievements
 - 17.3.4 Mergers and Acquisitions
 - 17.3.5 Certifications
 - 17.4 Sun Pharmaceutical Industries Ltd
 - 17.4.1 Financial Analysis
 - 17.4.2 Product Portfolio
 - 17.4.3 Demographic Reach and Achievements
 - 17.4.4 Mergers and Acquisitions
 - 17.4.5 Certifications
 - 17.5 Lupin
 - 17.5.1 Financial Analysis
 - 17.5.2 Product Portfolio
 - 17.5.3 Demographic Reach and Achievements

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.5.4 Mergers and Acquisitions
- 17.5.5 Certifications
- 17.6 AstraZeneca
 - 17.6.1 Financial Analysis
 - 17.6.2 Product Portfolio
 - 17.6.3 Demographic Reach and Achievements
 - 17.6.4 Mergers and Acquisitions
 - 17.6.5 Certifications
- 17.7 Almirall, S.A
 - 17.7.1 Financial Analysis
 - 17.7.2 Product Portfolio
 - 17.7.3 Demographic Reach and Achievements
 - 17.7.4 Mergers and Acquisitions
 - 17.7.5 Certifications
- 17.8 Takeda Pharmaceutical Company Limited
 - 17.8.1 Financial Analysis
 - 17.8.2 Product Portfolio
 - 17.8.3 Demographic Reach and Achievements
 - 17.8.4 Mergers and Acquisitions
 - 17.8.5 Certifications
- 17.9 GSK plc
 - 17.9.1 Financial Analysis
 - 17.9.2 Product Portfolio
 - 17.9.3 Demographic Reach and Achievements
 - 17.9.4 Mergers and Acquisitions
 - 17.9.5 Certifications
- 17.10 Bausch + Lomb
 - 17.10.1 Financial Analysis
 - 17.10.2 Product Portfolio
 - 17.10.3 Demographic Reach and Achievements
 - 17.10.4 Mergers and Acquisitions
 - 17.10.5 Certifications
- 17.11 Novartis AG
 - 17.11.1 Financial Analysis
 - 17.11.2 Product Portfolio
 - 17.11.3 Demographic Reach and Achievements
 - 17.11.4 Mergers and Acquisitions
 - 17.11.5 Certifications
- 17.12 Sanofi
 - 17.12.1 Financial Analysis
 - 17.12.2 Product Portfolio
 - 17.12.3 Demographic Reach and Achievements
 - 17.12.4 Mergers and Acquisitions
 - 17.12.5 Certifications
- 17.13 Pfizer Inc.
 - 17.13.1 Financial Analysis
 - 17.13.2 Product Portfolio

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.13.3 Demographic Reach and Achievements
- 17.13.4 Mergers and Acquisitions
- 17.13.5 Certifications
- 17.14 Fresenius SE & Co. KGaA
 - 17.14.1 Financial Analysis
 - 17.14.2 Product Portfolio
 - 17.14.3 Demographic Reach and Achievements
 - 17.14.4 Mergers and Acquisitions
 - 17.14.5 Certifications
- 17.15 Hikma Pharmaceuticals PLC
 - 17.15.1 Financial Analysis
 - 17.15.2 Product Portfolio
 - 17.15.3 Demographic Reach and Achievements
 - 17.15.4 Mergers and Acquisitions
 - 17.15.5 Certifications
- 17.16 Aurobindo Pharma
 - 17.16.1 Financial Analysis
 - 17.16.2 Product Portfolio
 - 17.16.3 Demographic Reach and Achievements
 - 17.16.4 Mergers and Acquisitions
 - 17.16.5 Certifications
- 18 Global Generic Drugs Market - Distribution Model (Additional Insight)
 - 18.1 Overview
 - 18.2 Potential Distributors
 - 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
 - 20.1 Very Small Companies
 - 20.2 Small Companies
 - 20.3 Mid-Sized Companies
 - 20.4 Large Companies
 - 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
 - 21.1 Government Funded
 - 21.2 Private Insurance
 - 21.3 Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Global Generic Drugs Market Report and Forecast 2024-2032

Market Report | 2024-07-17 | 200 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4999.00
	Five User License	\$5999.00
	Corporate License	\$6999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-06"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com